Remedium Bio announces the receipt of a National Science Foundation (NSF) Phase I Small Business Innovation Research (SBIR) grant to support the development of the Prometheus™ dose-adjustable gene therapy platform technology. Dr. Zou is Co-Investigator on this funded project. Our collaboration with them on this project in targeting metabolic disease is extended for another 12 months.